Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piero Antuono

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Age (Dordrecht, Netherlands)|July 11, 2013
Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study "Treviso Longeva (TRELONG)"Diego Albani, Eleonora Ateri, Stefano Mazzuco, et al.
The Lancet. Neurology|August 1, 2008
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factorsRaj N Kalaria, Gladys E Maestre, Raul Arizaga, et al.
The Lancet. Neurology|February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Axel Rominger, Peter Bartenstein, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Age (Dordrecht, Netherlands)|July 11, 2013
Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the prospective study "Treviso Longeva (TRELONG)"Diego Albani, Eleonora Ateri, Stefano Mazzuco, et al.
The Lancet. Neurology|August 1, 2008
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factorsRaj N Kalaria, Gladys E Maestre, Raul Arizaga, et al.
The Lancet. Neurology|February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trialRichard Dodel, Axel Rominger, Peter Bartenstein, et al.
Pageof 3